Latest Novartis Stories
Exemplary companies and organizations to be honored March 3 during 2015 ASAP Global Alliance Summit for outstanding partnering, alliance programs, and collaboration efforts ranging from combatting
CRANFIELD, England, February 26, 2015 /PRNewswire/ -- Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most successful
- Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD1 EAST HANOVER, N.J., Feb.
As Syngenta Lawsuit Filing Continue Wright & Schulte LLC Is Holding A Series of Public Meetings To Provide Important Legal Information to Ohio Farmers Who May Have Incurred Significant Financial
RnRMarketResearch.com adds "Acute Heart Failure - Pipeline Review, H1 2015" report to its store.
- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) EAST HANOVER, N.J., Feb.
NEW YORK, Feb.
BASEL, Switzerland, Feb. 13, 2015 /PRNewswire/ -- Syngenta announced that the 2014 Annual Report on Form 20-F has been filed with the U.S.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.